<SEC-DOCUMENT>0000950170-22-011219.txt : 20220606
<SEC-HEADER>0000950170-22-011219.hdr.sgml : 20220606
<ACCEPTANCE-DATETIME>20220606160122
ACCESSION NUMBER:		0000950170-22-011219
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220606
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220606
DATE AS OF CHANGE:		20220606

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adicet Bio, Inc.
		CENTRAL INDEX KEY:			0001720580
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813305277
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38359
		FILM NUMBER:		22998029

	BUSINESS ADDRESS:	
		STREET 1:		200 CLARENDON  STREET
		STREET 2:		FLOOR 6
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-482-2333

	MAIL ADDRESS:	
		STREET 1:		200 CLARENDON  STREET
		STREET 2:		FLOOR 6
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	resTORbio, Inc.
		DATE OF NAME CHANGE:	20171024
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>acet-20220606.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-06-06T15:32:59.5286+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:acet="http://www.adicetbio.com/20220606">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_ef037f61-6ad0-4055-9009-819ff56a7fa9" name="dei:EntityCentralIndexKey" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9">0001720580</ix:nonNumeric><ix:nonNumeric id="F_b8e1a53d-fe37-48c6-a4ce-9b316bc0938c" name="dei:AmendmentFlag" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9">false</ix:nonNumeric><ix:nonNumeric id="F_c649e885-d299-4f7e-ba3e-d03cbb92e84e" name="dei:SecurityExchangeName" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9">NONE</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="acet-20220606.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-06</xbrli:startDate><xbrli:endDate>2022-06-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="border-top:2.250pt double rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.75pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1bd59a85-437c-45b6-9d14-04e14326068b" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da1204b8-f391-41a2-ab79-08cd84a9c15e" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">June 06, 2022</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_770a5ef8-73a9-44a5-905d-315e1d1b0916" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:24.0pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:19.399%;"></td>
    <td style="width:3.813%;"></td>
    <td style="width:19.399%;"></td>
    <td style="width:17.618%;"></td>
    <td style="width:39.772%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0c1ddf70-f51d-4c86-a7d7-0e9e228be0bf" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b550227d-df4d-4af1-9664-8d8a97765c33" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">001-38359</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7edf5655-e92d-4ade-941d-eae53f9c79a7" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">81-3305277</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(State or Other Jurisdiction<br />of Incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(IRS Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_775c17d8-ff43-4497-938e-b3cb04486452" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">200 Clarendon Street</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0ae06d7-e592-4b27-bf5c-05966b5d6eda" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Floor 6</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_516c03ea-5e44-4112-a42d-29a1c0d47484" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Boston</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2fb27602-ca3e-4a27-9896-5b26108d1e98" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f0e6ead1-a3d9-4d90-a4c6-a3a084ba6978" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">02116</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#x2019;s Telephone Number, Including Area Code:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3b14d19-5417-4d7f-a1f2-f23a7f301adc" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b1c9402-a1dc-46bf-9a6c-2938a40d049a" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">503-9095</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f0173658-c870-45cd-9ca9-ca73a917e484" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:EntityInformationFormerLegalOrRegisteredName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Not applicable</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9.0pt;line-height:1.15;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d89ea4c-a5f5-4538-aa6d-9bd4798ed506" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.15;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bd3e5a8a-fb3b-4d78-a03e-715dff0ca958" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.15;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a8ce36fc-456d-4750-b8b4-30e50e9906dc" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.15;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78ff6c88-9c85-460d-a4c5-730602c85f42" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:37.996%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><br />Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Trading<br />Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><br />Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88dfc281-032c-4417-8842-8a5885769520" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a8a90098-9f88-4c50-accd-6e872264997d" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ACET</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c649e885-d299-4f7e-ba3e-d03cbb92e84e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Nasdaq Global Market</span></span></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x202f;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x202f;240.12b-2 of this chapter).</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_9a3a4f13-f9a8-4f2f-b78b-d17a87f8c56e" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_12b99de4-06bc-472b-8b07-ac0f44b9191a" contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On June 6, 2022, Adicet Bio, Inc. (&#x201c;Adicet&#x201d; or the &#x201c;Company&#x201d;) issued a press release titled &#x201c;Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting,&#x201d; a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 8.01 Other Events.</span></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On June 6, 2022, the Company issued a press release and presented on interim data from the Company&#x2019;s Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin&#x2019;s Lymphoma (NHL). Data highlights as of the May 31, 2022 data-cut date are as follows:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Of the eight evaluable patients, three received ADI-001 at dose level 1 (30 million CAR+ cells), three received ADI-001 at dose level 2 (100 million CAR+ cells) and two received ADI-001 at dose level 3 (300 million CAR+ cells). There are currently no patients with indolent lymphoma, such as follicular lymphoma, enrolled in the study.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Patients were heavily pretreated with a median number of prior therapies of 4 (range 2-5) and had a poor prognostic outlook as indicated by the median International Prognostic Index (IPI) score of 4 (range 2-5).</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ADI-001 treatment demonstrated a 75% overall response rate (ORR) and complete response (CR) in the study across all dose levels. In dose levels 2 and 3 combined, ADI-001 demonstrated an 80% ORR and CR rate.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In three patients that previously relapsed after prior autologous anti-CD19 CAR T therapy, treatment with ADI-001 demonstrated 100% ORR and CR rate. These patients included a triple-hit high grade B-cell lymphoma patient with prior exposure to Liso-cel, as well as a DLBCL patient and a double-hit high grade B-cell lymphoma patient who had previously achieved a PR to Axi-cel.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Early data indicate encouraging durable anti-tumor responses with potential for dose related increase in durability. 50% (2 of 4) of evaluable patients with at least six months follow up remain cancer free.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Detection of circulating ADI-001 in the blood by flow cytometry indicated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> expansion and dose-related increase of ADI-001 exposure in patients.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ADI-001 was well tolerated in the study to date. There were no occurrences of dose-limiting toxicities, graft vs host disease (GvHD), or Grade 3 or higher Cytokine Release Syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) reported.  There were no infections associated with enhanced lymphodepletion (eLD).</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Table 1:  Summary of ADI-001 interim data from three dosing cohorts: *</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <hr style="page-break-after:always;" />
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:87.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.923%;"></td>
    <td style="width:11.923%;"></td>
    <td style="width:24.773%;"></td>
    <td style="width:13.757%;"></td>
    <td style="width:11.923%;"></td>
    <td style="width:10.099%;"></td>
    <td style="width:15.602%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Dose Level</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Age/Sex</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">B-cell lymphoma subtypes</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"># prior lines of therapies</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Time since ADI-001 initial dosing (months)</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Prior CAR T?</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">BOR by Lugano Criteria 2014</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td rowspan="3" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">DL 1</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">30 million CAR+ cells</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">62/F</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Transformed DLBCL&#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(from chronic lymphocytic leukemia)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5 prior lines</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&gt;6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">No</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">PD</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">66/F</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Transformed high grade&#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">B-cell lymphoma (from follicular lymphoma)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4 prior lines</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">  </span>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&gt;6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">No</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CR</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">75/M</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Triple-hit high grade B-cell lymphoma</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5 prior lines</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&gt;6</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CR</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td rowspan="3" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">DL 2</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">100 million CAR+ cells</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">62/M</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Mantle cell lymphoma</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5 prior lines</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&gt;6</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">No</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CR</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">45/M</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Diffuse large B-cell lymphoma</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3 prior lines</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3-6</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">No</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">PD</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">61/M</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Diffuse large B-cell lymphoma</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2 prior lines</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3-6</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">No</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CR</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td rowspan="2" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">DL 3</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">300 million CAR+ cells</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">62/M</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Double-hit high grade B-cell lymphoma</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4 prior lines</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3-6</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CR</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">64/F</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Diffuse large B-cell lymphoma</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4 prior lines</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1-3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Yes</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CR</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(43,43,43,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">*Efficacy-evaluable patients as of the May 31, 2022 data-cut date.  Data are subject to further review and verification.</span><span style="color:rgba(43,43,43,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(43,43,43,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">BOR= best overall response. PD=progressive disease.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Table 2: ADI-001 Preliminary Efficacy Data:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(Per protocol analysis, independent radiographic assessment using Lugano 2014)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:17.649%;"></td>
    <td style="width:15.426%;"></td>
    <td style="width:15.406%;"></td>
    <td style="width:15.406%;"></td>
    <td style="width:15.406%;"></td>
    <td style="width:20.708%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">DL1 (3E7)&#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(N=3)</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">DL2 (1E8)&#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(N=3)</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">DL3 (3E8)&#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(N=2)</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total&#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(N=8)</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Prior CD19 &#x200b;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CAR-T &#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(N=3)</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ORR / BOR</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">67% (2/3)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">67% (2/3)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">100% (2/2)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">75% (6/8)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">100% (3/3)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CR, % (N)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">67% (2/3)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">67% (2/3)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">100% (2/2)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">75% (6/8)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">100% (3/3)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(43,43,43,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">*Efficacy-evaluable patients as of the May 31, 2022, data-cut date.  Data are subject to further review and verification.</span><span style="color:rgba(43,43,43,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of the May 31, 2022, data-cut date, of the six patients who achieved CR:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Dose level 1:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As previously disclosed, one patient administered ADI-001 in dose level 1, a 66-year-old female who had achieved a CR, developed COVID-19 related pneumonia approximately two and a half months after ADI-001 administration and later died of complications from it, unrelated to ADI-001.  This patient was previously reported as a partial response (PR) by local radiological assessment and has been assessed as a CR by independent central reading.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">One patient with triple-hit high grade B-cell lymphoma in dose level 1 who had relapsed following two prior treatments with autologous anti-CD19 CAR T therapy, had a CR after treatment with ADI-001. The patient developed a local skin relapse at four months, and was administered local radiotherapy. The skin lesion resolved with no systemic therapy provided to the patient. The patient continues to be cancer free seven and a half months following administration of ADI-001, as measured by a negative PET/CT scan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Dose level 2:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Both patients administered ADI-001 in dose level 2 have ongoing CR.  One patient has a CR beyond seven</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">months and one patient has a CR beyond four and a half months.</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Dose level 3:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Both patients administered ADI-001 in dose level 3 have ongoing CR with follow-up beyond three and one month, respectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In summary, 50% of evaluable patients with at least six months follow up (2 of 4) remain cancer free.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Table 3: ADI-001 Preliminary Safety Data in Efficacy-Evaluable Patients</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">+</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:17.358%;"></td>
    <td style="width:11.417%;"></td>
    <td style="width:10.651%;"></td>
    <td style="width:10.499%;"></td>
    <td style="width:9.743%;"></td>
    <td style="width:10.348%;"></td>
    <td style="width:10.197%;"></td>
    <td style="width:9.743%;"></td>
    <td style="width:10.045%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">DL1 (3E7)&#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">N=3</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">DL2 (1E8)&#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">N=3</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">DL3 (3E8)&#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">N=2</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total&#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">N=8</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Adverse Event Types</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">All &#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Grade&#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">N (%)</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Gr &#x2265;3&#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">N (%)</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">All &#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Grade &#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">N (%)</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Gr &#x2265;3&#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">N (%)</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">All &#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Grade &#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">N (%)</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x200b;Gr &#x2265;3&#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">N (%)</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">All</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Grade &#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">N (%)</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Gr &#x2265;3&#x200b;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">N (%)</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CRS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2 (67%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2 (25)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ICANS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1 (33%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1 (13)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">GvHD</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">DLTs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Infection*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1(33%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1(33%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1 (13)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1 (13)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">SAE - TEAE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1(33%)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1(33%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1 (33%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0 (0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2 (25)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1 (13)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">+</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Safety assessment was performed using the Common Terminology Criteria for Adverse Events (v5) and the American Society for Transplantation and Cellular Therapy criteria. The two ADI-001-related adverse events of special interest (AESI) were a Grade 1 CRS at DL1 and a Grade 1 ICANS at DL2, which resolved within 24 hours without medical intervention&#x200b;; No DLTs or GvHD; No treatment discontinuations due to AEs&#x200b;; two patients administered standard lymphodepletion (sLD) and six patients eLD&#x200b;; There were no eLD-associated clinical infection.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">*One patient in DL 1 who received sLD developed COVID-19 pneumonia later died of complications of it, unrelated to ADI-001.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Given the safety profile to date, the protocol was amended to include a new DL 4 (1E9 CAR+ cells) and a potential ADI-001 consolidation dosing at DL3 to finalize the recommended Phase 2 dose in the second half of 2022. The Company expects to backfill enrollment to DL3 with additional potential patients in the second half of 2022. The Company expects to provide at least one additional clinical update for the ADI-001 Phase 1 study in the second half of 2022. The Company will discuss with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) the design of two pivotal intent studies and a potential path to support a Biologics License Application (BLA) and Marketing Authorization Application (MAA) for ADI-001 and initiate at least one potentially pivotal study in the first half of 2023.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Adicet has six additional internal gamma delta T cell therapy programs in preclinical development and plans one new investigational new drug application (IND) every 12-18 months, including one new IND in 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The disclosure under this Item 8.01 contains &#34;forward-looking statements&#34; of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business and operations of Adicet. These forward-looking statements include, but are not limited to, express or implied statements regarding: the potential safety, durability, tolerability and therapeutic effects of ADI-001, including the expected design, implementation, timing of success of ADI-0001; plans and timing for the release of additional clinical data from Adicet&#x2019;s Phase 1 trial of ADI-001 in relapsed/refractory NHL patients; future progress of the GLEAN study, including ongoing patient enrollment; expectations regarding future regulatory filings for product candidates in the Company&#x2019;s pipeline; the outcome of discussions with the FDA and EMA regarding the design of two pivotal studies and a BLA and MAA submission for ADI-001; and timing of a dose selection for the Phase 2 trial in the second half of 2022 and initiation of a potentially pivotal program in the first half of 2023.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of COVID-19 on Adicet&#x2019;s business and financial results, including with respect to disruptions to Adicet&#x2019;s clinical trials, business operations and ability to raise additional capital; Adicet's ability to execute on its strategy, including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results, including interim results, from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; clinical studies may fail to demonstrate adequate safety and efficacy of Adicet&#x2019;s product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; and regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet's actual results to differ from those</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">contained in the forward-looking statements, see the section entitled &#34;Risk Factors&#34; in Adicet's most recent Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent filings with the Securities and Exchange Commission. All disclosure under this Item 8.01 is as of the date of this Form 8-K, and Adicet undertakes no duty to update this information unless required by law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.0%;"></td>
    <td style="width:2.004%;"></td>
    <td style="width:87.996%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="/exhibit" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">99.1</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="acet-ex99_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Press Release of Adicet Bio, Inc. on June 6, 2022, furnished herewith.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6.002%;"></td>
    <td style="width:43.998%;"></td>
    <td style="width:7.004%;"></td>
    <td style="width:42.996%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.05;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ADICET BIO, INC.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Date:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">June 6, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Chen Schor</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;&#160;Name:</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;&#160;&#160;Title:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.7pt;line-height:1.05;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Chen Schor<br />President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>acet-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img94724212_0.jpg" alt="img94724212_0.jpg" style="width:310px;height:96px;">&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Exhibit 99.1</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Arial;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high grade aggressive Non-Hodgkin&#x2019;s Lymphoma (NHL), as of May 31, 2022 data-cut date</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">80% ORR and CR rate at dose levels 2 and 3 combined</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">100% ORR and CR rate in three anti-CD19 CAR-T relapsed patients</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">50% of evaluable patients with at least six months follow-up remain cancer free</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Dose-related increase of ADI-001 exposure observed in blood</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Company expects to identify recommended Phase 2 dose in second half of 2022 and initiate at least one potentially pivotal study in first half of 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Company to host webcast today at 1:30pm PT / 4:30pm ET</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Redwood City, CA and Boston &#x2013; June 6, 2022 &#x2013; Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced emerging positive safety and efficacy data from the Company&#x2019;s Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin&#x2019;s Lymphoma (NHL) in an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting on June 6, 2022. The presentation outlines a summary of clinical data as of a May 31, 2022, data-cut date.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">&#x201c;Adicet is a pioneer in the field of gamma delta CAR T cell therapies and it is gratifying to see the highly encouraging clinical data for ADI-001 unfold as a potential best-in-class therapy for NHL,&#x201d; said Chen Schor, President and Chief Executive Officer of Adicet Bio. &#x201c;Notably, with a favorable safety and tolerability profile, treatment to date with ADI-001 demonstrated an impressive CR rate, including 100% in CAR-T relapsed patients, and very encouraging durability of response. We look forward to discussing the data in more detail and outlining next steps in our webcast this afternoon.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Arial;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">&#x201c;It is impressive to see 50 percent of six-month evaluable patients cancer free beyond seven months. One of these patients had previously relapsed after two treatments with autologous anti-CD19 CAR T and now remains cancer free seven and a half months following administration of ADI-001, suggesting the patient has had major clinical benefit from ADI-001. This is particularly notable because patients who relapse after autologous anti-CD19 CAR T have dismal outcomes with a median survival of approximately six months,&#x201d; said Sattva Neelapu, M.D., Professor in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center. &#x201c;When we look at the totality of these early data, we have an indicator that allogeneic gamma-delta CAR T cell therapy like ADI-001 could be a significant advance.&#x201d;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Arial;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">&#x201c;NHL remains a disease that is very difficult to treat, especially in high-risk patients with aggressive disease. Our study is enrolling patients with aggressive B-cell lymphoma, including patients with double-hit and triple-hit high-grade B cell lymphoma and patients who had a prior relapse to autologous anti-CD19 CAR T therapy,&#x201d; said Francesco Galimi, M.D., Ph.D., Senior Vice President and Chief Medical Officer of Adicet Bio. &#x201c;We are encouraged by the CRs observed to date in the Phase 1 study and are committed to rapidly advancing ADI-001 into a potential pivotal program.&#x201d;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Arial;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Data highlights as of the May 31, 2022 data-cut date included in the ASCO presentation are as follows:</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Of the eight evaluable patients, three received ADI-001 at dose level 1 (30 million CAR+ cells), three received ADI-001 at dose level 2 (100 million CAR+ cells) and two received ADI-001 at dose level 3 (300 million CAR+ cells). There are currently no patients with indolent lymphoma, such as follicular lymphoma, enrolled in the study.</font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Patients were heavily pretreated with a median number of prior therapies of 4 (range 2-5) and had a poor prognostic outlook as indicated by the median International Prognostic Index (IPI) score of 4 (range 2-5).</font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">ADI-001 treatment demonstrated a 75% overall response rate (ORR) and complete response (CR) in the study across all dose levels. In dose levels 2 and 3 combined, ADI-001 demonstrated an 80% ORR and CR rate.</font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">In three patients that previously relapsed after prior autologous anti-CD19 CAR T therapy, treatment with ADI-001 demonstrated 100% ORR and CR rate. These patients included a triple-hit high grade B-cell lymphoma patient with prior exposure to Liso-cel, as well as a DLBCL patient and a double-hit high grade B-cell lymphoma patient who had previously achieved a PR to Axi-cel.</font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Early data indicate encouraging durable anti-tumor responses with potential for dose related increase in durability. 50% (2 of 4) of evaluable patients with at least six months follow up remain cancer free.</font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Detection of circulating ADI-001 in the blood by flow cytometry indicated in vivo expansion and dose-related increase of ADI-001 exposure in patients.</font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">ADI-001 was well tolerated in the study to date. There were no occurrences of dose-limiting toxicities, graft vs host disease (GvHD), or Grade 3 or higher Cytokine Release Syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) reported.  There were no infections associated with enhanced lymphodepletion (eLD).</font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Table 1:  Summary of ADI-001 interim data from three dosing cohorts: *</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:87.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.849%;"></td>
    <td style="width:11.924%;"></td>
    <td style="width:24.381%;"></td>
    <td style="width:13.727%;"></td>
    <td style="width:12.703%;"></td>
    <td style="width:10.015%;"></td>
    <td style="width:15.401%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Dose Level</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Age/Sex</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">B-cell lymphoma subtypes</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;"># prior lines of therapies</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Time since ADI-001 initial dosing (months)</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Prior CAR T?</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">BOR by Lugano Criteria 2014</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td rowspan="3" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">DL 1</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">30 million CAR+ cells</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">62/F</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Transformed DLBCL&#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">(from chronic lymphocytic leukemia)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">5 prior lines</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">&gt;6</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">No</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">PD</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">66/F</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Transformed high grade&#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">B-cell lymphoma (from follicular lymphoma)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">4 prior lines</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">&gt;6</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">No</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">CR</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">75/M</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Triple-hit high grade B-cell lymphoma</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">5 prior lines</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">&gt;6</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Yes</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">CR</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td rowspan="3" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">DL 2</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">100 million CAR+ cells</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">62/M</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Mantle cell lymphoma</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">5 prior lines</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">&gt;6</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">No</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">CR</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">45/M</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Diffuse large B-cell lymphoma</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">3 prior lines</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">3-6</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">No</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">PD</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">61/M</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Diffuse large B-cell lymphoma</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">2 prior lines</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">3-6</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">No</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">CR</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td rowspan="2" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">DL 3</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">300 million CAR+ cells</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">62/M</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Double-hit high grade B-cell lymphoma</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">4 prior lines</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">3-6</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Yes</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">CR</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">64/F</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Diffuse large B-cell lymphoma</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">4 prior lines</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">1-3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Yes</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">CR</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(43,43,43,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">*Efficacy-evaluable patients as of the May 31, 2022 data-cut date.  Data are subject to further review and verification.  BOR= best overall response. PD=progressive disease.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Table 2: ADI-001 Preliminary Efficacy Data:</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">(Per protocol analysis, independent radiographic assessment using Lugano 2014)</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:17.649%;"></td>
    <td style="width:15.416%;"></td>
    <td style="width:15.416%;"></td>
    <td style="width:15.416%;"></td>
    <td style="width:15.416%;"></td>
    <td style="width:20.687%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">DL1 (3E7)&#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">(N=3)</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">DL2 (1E8)&#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">(N=3)</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">DL3 (3E8)&#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">(N=2)</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Total&#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">(N=8)</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Prior CD19 &#x200b;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">CAR-T &#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">(N=3)</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">ORR / BOR</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">67% (2/3)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">67% (2/3)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">100% (2/2)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">75% (6/8)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">100% (3/3)</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">CR, % (N)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">67% (2/3)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">67% (2/3)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">100% (2/2)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">75% (6/8)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">100% (3/3)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(43,43,43,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">*Efficacy-evaluable patients as of the May 31, 2022, data-cut date.  Data are subject to further review and verification.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(43,43,43,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">  </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">As of the May 31, 2022, data-cut date, of the six patients who achieved CR:</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Arial;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Dose level 1:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">As previously disclosed, one patient administered ADI-001 in dose level 1, a 66-year-old female who had achieved a CR, developed COVID-19 related pneumonia approximately two and a half months after ADI-001 administration and later died of complications from it, unrelated to ADI-001.  This</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">patient was previously reported as a partial response (PR) by local radiological assessment and has been assessed as a CR by independent central reading.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">One patient with triple-hit high grade B-cell lymphoma in dose level 1 who had relapsed following two prior treatments with autologous anti-CD19 CAR T therapy, had a CR after treatment with ADI-001. The patient developed a local skin relapse at four months, and was administered local radiotherapy. The skin lesion resolved with no systemic therapy provided to the patient. The patient continues to be cancer free seven and a half months following administration of ADI-001, as measured by a negative PET/CT scan.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Arial;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Dose level 2:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Both patients administered ADI-001 in dose level 2 have ongoing CR.  One patient has a CR beyond seven</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">months and one patient has a CR beyond four and a half months.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Arial;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Dose level 3:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Both patients administered ADI-001 in dose level 3 have ongoing CR with follow-up beyond three and one month, respectively.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Arial;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">In summary, 50% of evaluable patients with at least six months follow up (2 of 4) remain cancer free.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Arial;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Table 3: ADI-001 Preliminary Safety Data in Efficacy-Evaluable Patients</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:Arial;min-width:fit-content;">+</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:17.356%;"></td>
    <td style="width:11.416%;"></td>
    <td style="width:10.66%;"></td>
    <td style="width:10.498%;"></td>
    <td style="width:9.742%;"></td>
    <td style="width:10.357%;"></td>
    <td style="width:10.196%;"></td>
    <td style="width:9.742%;"></td>
    <td style="width:10.034%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">DL1 (3E7)&#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">N=3</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">DL2 (1E8)&#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">N=3</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">DL3 (3E8)&#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">N=2</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Total&#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">N=8</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Adverse Event Types</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">All &#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Grade&#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">N (%)</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Gr &#x2265;3&#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">N (%)</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">All &#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Grade &#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">N (%)</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Gr &#x2265;3&#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">N (%)</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">All &#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Grade &#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">N (%)</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">&#x200b;Gr &#x2265;3&#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">N (%)</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">All</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Grade &#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">N (%)</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">Gr &#x2265;3&#x200b;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">N (%)</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">CRS</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">2 (67%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">2 (25)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0)</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">ICANS</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">1 (33%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">1 (13)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0)</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">GvHD</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0)</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">DLTs</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0)</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Infection*</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">1(33%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">1(33%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">1 (13)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">1 (13)</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Arial;min-width:fit-content;">SAE - TEAE</font></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">1(33%)</font></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">1(33%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">1 (33%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">0 (0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">2 (25)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">1 (13)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:Arial;min-width:fit-content;">+</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Safety assessment was performed using the Common Terminology Criteria for Adverse Events (v5) and the American Society for Transplantation and Cellular Therapy criteria. The two ADI-001-related adverse events of special interest (AESI) were a Grade 1 CRS at DL1 and a Grade 1 ICANS at DL2, which resolved within 24 hours without medical intervention&#x200b;; No DLTs or GvHD; No treatment discontinuations due to AEs&#x200b;; two patients administered standard lymphodepletion (sLD) and six patients eLD&#x200b;; There were no eLD-associated clinical infection.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Arial;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">*One patient in DL 1 who received sLD developed COVID-19 pneumonia later died of complications of it, unrelated to ADI-001.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Arial;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Given the safety profile to date, the protocol was amended to include a new DL 4 (1E9 CAR+ cells) and a potential ADI-001 consolidation dosing at DL3 to finalize the recommended Phase 2 dose in the second half of 2022.  The Company expects to provide at least one additional clinical update for the ADI-001 Phase 1 study in the second half of 2022.  The Company will discuss with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) the design of two pivotal intent studies and a potential path to support a Biologics License Application (BLA) and Marketing</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Authorization Application (MAA) for ADI-001 and initiate at least one potentially pivotal study in the first half of 2023.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Arial;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Details of the ASCO Oral Presentation:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Arial;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Abstract Number:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> 7509<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Abstract Title:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> A Phase 1 Study of ADI-001: Anti-CD20 CAR-engineered Allogeneic Gamma Delta (&#x3b3;&#x3b4;) T cells in Adults with B-cell Malignancies<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Presenting Author:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> Sattva Neelapu, M.D., The University of Texas MD Anderson Cancer Center<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Session Type/Title:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> Clinical Science Symposium/ Beating Bad Blood: The Power of Immunotherapy in Hematologic Malignancies<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Date:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> Monday, June 6, 2022<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Time:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> 8:00 AM-9:30 AM CDT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Webcast/ Conference Call information</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">The Company will host a conference call and webcast today, June 6, 2022, at 4:30pm ET to discuss the results. The live webcast of the presentation can be accessed under &#x201c;Presentations &amp; Events&#x201d; in the investors section of the Company&#x2019;s website at www.adicetbio.com or by dialing (877) 800-3802 (domestic) or +1 (615) 622-8057 (international) and referencing the conference ID 5466375. The archived webcast will be available on the Company's website beginning approximately two hours after the event.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">About ADI-001</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"><br>ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent anti-tumor activity in preclinical models, leading to long-term control of tumor growth. In April 2022, ADI-001 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of relapsed or refractory B-cell NHL.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">About the GLEAN Study </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"><br>This Phase 1 study is an open-label, multi-center study of ADI-001 enrolling adults diagnosed with B-cell malignancies who have either relapsed, or are refractory to at least two prior regimens. The primary objectives of the study are to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ADI-001, and to determine optimal dosing as a monotherapy. The study is expected to enroll approximately 75 patients. For more information about the clinical study design, please visit </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Arial;min-width:fit-content;">www.clinicaltrials.gov</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Arial;min-width:fit-content;">NCT04735471</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">About Adicet Bio, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of &#x201c;off-the-shelf&#x201d; gamma delta T cells, engineered with CAR and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Arial;min-width:fit-content;">www.adicetbio.com</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Available Information</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2170833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Adicet announces material information to the public about the Company, its product candidates and clinical trials, and other matters through a variety of means, including filings with the U.S. Securities and Exchange Commission (SEC), press releases, public conference calls, webcasts, the investor</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2170833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">relations section of the Company website at investor.adicetbio.com and the Company&#x2019;s Twitter account (@AdicetBio), in order to achieve broad, non-exclusionary distribution of information to the public and for complying with its disclosure obligations under Regulation FD.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2170833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Arial;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Forward-Looking Statements</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">This press release contains &#34;forward-looking statements&#34; of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business and operations of Adicet. These forward-looking statements include, but are not limited to, express or implied statements regarding the potential safety, durability, tolerability and therapeutic effects of ADI-001, including the expected design, implementation, timing and success of ADI-001, plans and timing for the release of additional clinical data from Adicet&#x2019;s Phase 1 trial of ADI-001 in relapsed/refractory NHL patients. Future progress of the GLEAN study, including ongoing patient enrollment; and timing of a dose selection for the Phase 2 trial in the second half of 2022 and initiation of a potentially pivotal program in the first half of 2023.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of COVID-19 on Adicet&#x2019;s business and financial results, including with respect to disruptions to Adicet&#x2019;s clinical trials, business operations and ability to raise additional capital; Adicet's ability to execute on its strategy, including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results, including interim results, from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; clinical studies may fail to demonstrate adequate safety and efficacy of Adicet&#x2019;s product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; and regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet's actual results to differ from those contained in the forward-looking statements, see the section titled &#34;Risk Factors&#34; in Adicet's most recent Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent filings with the SEC. All information in this press release is as of the date of the release, and Adicet undertakes no duty to update this information unless required by law.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Adicet Bio., Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Investor and Media Contacts</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Anne Bowdidge</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">abowdidge@adicetbio.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Janhavi Mohite</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Stern Investor Relations, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">212-362-1200</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">janhavi.mohite@sternir.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img94724212_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img94724212_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "; ?,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*R/$7B2P\,Z>;R_8A,X 7DFA*^@&O17!:3\6O#VL:C%8P"=9)3A2Z8%=X""
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
*%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>acet-20220606.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-06-06T15:32:58.8581+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.adicetbio.com/20220606" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:acet="http://www.adicetbio.com/20220606" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acet-20220606_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acet-20220606_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>acet-20220606_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-06-06T15:32:58.8938+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="acet-20220606.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10200.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="10150.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>acet-20220606_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-06-06T15:32:58.9146+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140582500382104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 06, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  06,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adicet Bio, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001720580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-3305277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Clarendon Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Floor 6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">503-9095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">Not applicable<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACET<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NONE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>acet-20220606_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="acet-20220606.xsd" xlink:type="simple"/>
    <context id="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2022-06-06</startDate>
            <endDate>2022-06-06</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_ef037f61-6ad0-4055-9009-819ff56a7fa9">0001720580</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_b8e1a53d-fe37-48c6-a4ce-9b316bc0938c">false</dei:AmendmentFlag>
    <dei:SecurityExchangeName
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_c649e885-d299-4f7e-ba3e-d03cbb92e84e">NONE</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_1bd59a85-437c-45b6-9d14-04e14326068b">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_da1204b8-f391-41a2-ab79-08cd84a9c15e">2022-06-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_770a5ef8-73a9-44a5-905d-315e1d1b0916">Adicet Bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_0c1ddf70-f51d-4c86-a7d7-0e9e228be0bf">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_b550227d-df4d-4af1-9664-8d8a97765c33">001-38359</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_7edf5655-e92d-4ade-941d-eae53f9c79a7">81-3305277</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_775c17d8-ff43-4497-938e-b3cb04486452">200 Clarendon Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_a0ae06d7-e592-4b27-bf5c-05966b5d6eda">Floor 6</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_516c03ea-5e44-4112-a42d-29a1c0d47484">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_2fb27602-ca3e-4a27-9896-5b26108d1e98">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_f0e6ead1-a3d9-4d90-a4c6-a3a084ba6978">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_a3b14d19-5417-4d7f-a1f2-f23a7f301adc">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_5b1c9402-a1dc-46bf-9a6c-2938a40d049a">503-9095</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_f0173658-c870-45cd-9ca9-ca73a917e484">Not applicable</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_7d89ea4c-a5f5-4538-aa6d-9bd4798ed506">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_bd3e5a8a-fb3b-4d78-a03e-715dff0ca958">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_a8ce36fc-456d-4750-b8b4-30e50e9906dc">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_78ff6c88-9c85-460d-a4c5-730602c85f42">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_88dfc281-032c-4417-8842-8a5885769520">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_a8a90098-9f88-4c50-accd-6e872264997d">ACET</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_9a3a4f13-f9a8-4f2f-b78b-d17a87f8c56e">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_8090d6f9-f1a2-432a-b796-d34773d7c9b9"
      id="F_12b99de4-06bc-472b-8b07-ac0f44b9191a">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "F QE0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  I@,94>#XJN^T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L0@$(9?I7A/QKB0@V2]=.FIA4(76GH3G=V5QD1T2K)O7V-WLY3V 0I>G/G]
MYANP,T&:,>)S' -&<ICN9M\/29JP92>B( &2.:'7J<Z)(3</8_2:\C4>(6CS
MH8\(@O,6/)*VFC0LP"JL1*8Z:Z2)J&F,%[PU*SY\QK[ K 'LT>- "9JZ ::6
MB>$\]QW<  N,,/KT74"[$DOU3VSI +LDY^36U#1-];0IN;Q# V]/CR]EW<H-
MB?1@,+]*3M(YX)9=)[]N[G?[!Z8$%Z+B;3Y[P25O9-.^+ZX__&["?K3NX/ZQ
M\550=?#K7Z@O4$L#!!0    ( "F QE297)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M*8#&5)< L]R2!   ,A(  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6RE
MF&UOZC84QU_??0H+[<4FT28QY:%7%(G2]JZ[?4"%[4J;]L(D!JPZ=F8[A7[[
M'0>:L+MP@K0WD)#XGY_/L<__D.%&FU>[YMR1;2J5O6JMG<L^!X&-USQE]EQG
M7,&5I38I<W!J5H'-#&=),2B5 0W#7I RH5JC8?';U(R&.G=2*#XUQ.9IRLS[
M-9=Z<]6*6A\_O(C5VOD?@M$P8RL^X^ZW;&K@+"A5$I%R9856Q/#E56L<?;ZF
M?3^@N.-WP3?VX)CXJ2RT?O4G]\E5*_1$7/+8>0D&7V]\PJ7T2L#Q]UZT53[3
M#SP\_E"_*R8/DUDPRR=:?A.)6U^U!BV2\"7+I7O1FU_X?D)=KQ=K:8M/LMG=
MVZ4M$N?6Z70_& A2H7;?;+L/Q,& BV,#Z'X +;AW#RHH;YACHZ'1&V+\W:#F
M#XJI%J,!3BB?E9DS<%7 .#>ZT7$.079DK!)RJYQP[^1>[;(-41L&#A[B;PWB
MO>#U3I >$?PU5^<D[+4)#2G]]_  V$I 6@+20J]S1&^BW[@A?XX7UAE(X5^(
M9*>4[!22%TUSGK]GO&Z&^/#!V5<$XJ*$N$!5QD"0%!1WDJWJ*/#Q2R8M1SBZ
M)4?WM&!,N1':KX&$P$JJC0NN5&2^U_[ATZ>&U/=*M!XJN%^.+WPE?/*!\8FE
MM6"XSC@1,=2W:Z';L+;C<P2M7Z+U3T&;0. ,DZ":\"WYRM_KX'"E, RC/@V[
M@Q#!&I18@U.P;E-N5D*MR!<8[]9DHM.,J5HX7,^9'%MCER76Y2E8=T)R\I2G
M"V[J4' -"--99]#I7B(\45A5O? 4(E@-VF3:%+6N368.%C[1!@*60V(AOSJI
M76\-ZC>W&.1!:8Y.@9RS+;E/8*6)I8@+4B2(#9(#"&(G[-)^'R.L:G-$3R$<
M)XGAUK8_#L@#W$>>57WL<$EH)\A$,@/5$28*5\#9,-:JZ$=XV499YQM=RXI+
MWDD-BZ6'X55V$.'U_'N\B3\#];G>U+LP+G>MH750&%EE$!%>U[\G*W?)U.@W
MH>+Z+..:CV,,K3*(Z"2'*-&F,&LHQW^([/C6Q15#&D5H0BN'B/#"7B1P#)WR
M<11<H-?%+"&J/"'"B_B#CB$FT[566/5M$.F&G;/+\+*+$55V$)WD!P=]9IOX
M'AL:O0>^ EA87#O7YX8G1UV_X2E/VA&691**YD)B-D8KVZ!X8?]FA'-<>4--
M<[6OQK:.K4&HJ7NCE4E0O*+/-$Q0.._VC[ OC6"RE@=7:>0Y:-?Q^CTU_"R&
M\' H#+LF&RHY)/9YN:Q?> UZC625 5"\6O^'[-[:',@: 7'91L#* NA)%G"[
M)7/H=JTHK'[7EM=R_;\_"+0R (H7Z[EPT+CI)8GH3XN?R8S'.>R#VG:R0<GO
MF\+5=?S:)ADSY(W)G),?PW/?!Y,,\F#78/X8=^4.%*_E$,7$[XO9>[K0];NB
MX8_#Y':.D51>0/%2_A$RR&V\9FK%C]:T!J&GYZ?:WC(X> /@WZ8\,O\'P!+)
MEZ 3GO<A+V;W@F)WXG16O!18:.=T6ARN.8-]X&^ ZTNMW<>)?\]0OB8:_0-0
M2P,$%     @ *8#&5)^@&_"Q @  X@P   T   !X;"]S='EL97,N>&ULW5=M
M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>Q
MS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G
M55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4
M)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(R
MA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[
M##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R
M 5KXK;J*W5<D].)3"6T@L-5)](1&,80)"L2_C!9B7X2]_:VPI!&/QGWL_&[T
MH'_OC./WEE>B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0<
MO(%;2AZY=>)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q
M]%P<T:L#.EL)7(0;^A7N5WGF0/:=D$[H43N*LN3ZQ3GUX1W;^PO\*KY?7_**
M==+M9G!#S_(77HI.Y?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9
MQP<<GB-WPQ-',)^ Q1' L#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR
M'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<
M8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)
MQI$\QQ"8Q?B,9AE2G0P^\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY[
M'R73>RHY_U=3_ 102P,$%     @ *8#&5)>*NQS     $P(   L   !?<F5L
M<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5Q
MD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC
M0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W
M\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ
M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  I@,94.JJBYT !   \ @
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MZ7FFUS>36TGHX-R#8._AE8P=S8\?=_<#4$L#!!0    ( "F QE0D'INBK0
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ *8#&5'@^*KOM    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M*8#&5)E<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    "  I@,94EP"SW)($   R$@  &
M    @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M*8#&5)^@&_"Q @  X@P   T              ( !U P  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    "  I@,94EXJ[',     3 @  "P              @ &P
M#P  7W)E;',O+G)E;'-02P$"% ,4    "  I@,94.JJBYT !   \ @  #P
M            @ &9$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ *8#&
M5"0>FZ*M    ^ $  !H              ( !!A(  'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ *8#&5&60>9(9 0  SP,  !,
M         ( !ZQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^
) @  -10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="acet-20220606.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="acet-20220606.htm">acet-20220606.htm</File>
    <File>acet-20220606.xsd</File>
    <File>acet-20220606_lab.xml</File>
    <File>acet-20220606_pre.xml</File>
    <File>acet-ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "acet-20220606.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "acet-20220606.htm"
     ]
    },
    "labelLink": {
     "local": [
      "acet-20220606_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "acet-20220606_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "acet-20220606.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 26,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 25,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "acet",
   "nsuri": "http://www.adicetbio.com/20220606",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "acet-20220606.htm",
      "contextRef": "C_8090d6f9-f1a2-432a-b796-d34773d7c9b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "role": "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "acet-20220606.htm",
      "contextRef": "C_8090d6f9-f1a2-432a-b796-d34773d7c9b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Legal or Registered Name of an entity",
        "label": "Entity Information, Former Legal or Registered Name"
       }
      }
     },
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000950170-22-011219-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-011219-xbrl.zip
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MS:7'PPHZ4,LR#KH+V34"'DRI1EO_>7I8X$GXRG1['6/N'QCQ2Z/_\>RKDJN
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M#QAG*K!@>?ZUT4=>%\ZGMQVSM^2 NB^S).23?A"*ZP<<^/A7D>4RF-3MJ\>
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MIYOM1.3%1<K5-@ ?_L",GR+/O!BK/'[IYU69L5GF']<"E#N'3)R7BXRI6G8
M9U!5I"[Z:#,'N'13;22VU>:XVXG%*E3.&2Y;Y"R3UPS(.!_5*7U6)-#*F$/%
M'H\\H/L ; -Q%7%5H_2+N&J5\-V#*-.KK[[U9.JIO6CX[I'*8ZMBSF$8QRH)
M%B!3>!, DLC3R5R"K"&7;#U\NP&,[%)>Q@WI]YW\ LXK;A:.(^65HBW0;MF"
MN<7CJ:\+PZN9GSB<.+Q1L"8.?XZ4XU4=T4)X+M**(>8RAA" ^G6(#02A5E2B
MF,5>N4;KE:LDBF%".2XOJ\WC:W5OK<A:&/\&.;O,V"@&_Q'$H[AG\^OE[WOE
M;KJO*D"V\$\,F,&#'("A^ [28Z?59IFS2>2G8#LPH7FF3M%)O.L0'.0@$+B1
M12TA:SS+8D^J(42B2..J&Q.639\_&.P>00VIVJ@J_#:[,2P9!:5EP^TMT]J4
M#RRB$3JX?A7$^P*3K<BPF^)P[P46:$S+L)V>5?_S]JCSE0Q+;\UVFYVK^,SH
M,W96C&$H"[O ENTBPUP=Z"<JIA>/<'-YG_VY:1NQ'GY49.%"S'D;BQG&G8??
MD-GK_O""S(6+=E753WLUD]$&"W+?79</*62"3>K>6Y,%AJN[BN9PCEWW_GL\
M.S=NZ7S4-4_E9)1J[>CZ':]EN4<9JUKJMS_>7<]/7-10U:EP]J,J%RZ&AF'V
M\$*(!UQ/=G^-TY=9JBK7[Y:(QFQ]WL/$V"&N<]Y[[TICX4@P:SS,=B_$]IFX
M)HP1QIX-8S=7%;-BF$\2<?]-QP0Z MUC0?=+M3Z.0ZY/@)3;)0EV!+OGNR8:
MRK%,O6UR%NQ*M=Q9!;>;Y<+D_5='$PP)AH_>6JZX3^U;^BL!C8#V?+[=\2FN
MG!X6%SR*V2"5ZOUOS-0-^\FW:J?Q%=;P<</:>."X*:="8/U13N60&?.H)+D]
M3&Y+#V,^\3I@LA=K!*55+JETS.TOA!W"SJ.B*[Q;$._V$7ZYJUUM<="'.^^'
MU5<ISDVU].J-TCB27I6?\R9XU#,4Q7<QEORI+S@B37VGT'+FTV\$HC4"T>ON
ML&FZ=!JD8K]=Y#L=4JTU4JT&@><H)N00<AZ56MY[H=?E$<+>*<(Z'<H0$':>
MGB&8'6RG-,$J]^^4:8,EU]A1MH"T]E$(L^_*%C1<A*\<*Y.*$3YF^*!D"B53
MWI%N-0@\E$PAY#SRY>VG:YQ,H9U1;PB)76?[&[$88>=Q29<'7%Y(X")PT4Z"
M]P0BVDFP)BIV*_AMN.@H[4;$LR:J];]DLYX-.H9I6UWH4O6/\::!M(), 9VG
M(GI;]7DJ<XW<AL;(;?G+Z<A.O!\=7/&!*LK<$78>A9UO/,I#P2A11UBB1-V[
M!1$EZM9$Q2A11XFZMT0\#5(MVL-#R'F'>W@(86N ,)OVYA!V'INCE4%0X"N3
M81RT)X= M1)0613JKRF(*-1?%Q73*-"G0/^MT$Z#%(L"?=J0LPH<K?4]*+0)
MYPTAL6-0>H"P0^D! E5#0&52>F!-043I@351,4H/4'K@[=!.@Q2+T@.$G-<_
MH6/2"9UWC,J5GM"QULA/:(S<+#JA\\YUD$[H$'::@)V]N!C2W3H$KI>]=Y=
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MPL-))K,60X$E0DF-I=R70#X\&4D/C%D&+#3&[XL,W#1V6%SP* :39MA;-^9
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M "( O<S!'EU7"#()082@1R&HZP" .ML] A !Z D49-UAQ"BJ(T2^</KJM,4
MD$=$:.\(/N24$X (0 2@MP$@BNH(0135$8!>G8+NB^KH"H77N$*A17<HO#:&
M5K,7Y'F/Z#=&C9Z=K'8?HB:MNDPFKV<:=C6*&?=&4EP*GPU.W_!Y?M*(]= (
MU8@OO#A5/-V'ZD2*XU@-P/9BO+\3X!XRH[^N8&L6]R1H8N,B"R=X18T7@H1]
M8)MH:L@9]^%QF8'+!RQ37RHB(^;/34:+<=;I:!/!4RT.?18(Z*-0!#7B_HRD
M.,,,IX\/Q0F2UO%_'^QIA@N&/@2:\UD2B6(<1Q(\@B1)XVLYAJ^A;_E5K+P
M#O6% 8,B^0A<C !Z->U3W=$2>ZHX5IK"P*!F(% O'B=AY4)D+$CC,9-YBQ51
MW3IX'E5EX)><CV0V%<(57Q!5*I(XQ2?@:PZ%P/_GL\M_V.;)Z18;3E@8>_@U
MWL41QA<8(LS?Q8$='$$%0R&BZONZQL$I/CY_H0<ZW:EJ@V.XL+;W"!'5-HD
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MM+@&_P;<'!B5!-FK?(.X6+1O0YRZVE*DXM^%S, )F;=>$#&D\27T$.M9\ C
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MT'@ 2M/GX16?9#L;;)O,ZU-$7D64PI_ZE#\P))D0M0NK_%3T3_,0GE7QYBE
MF7TI(5H&H#*: 7(<@ZN*ZU* X]TH0G">"I5\A8J^8)1IZ-H?4]=Y(GC*RI3[
M'CRDC*T%$1DXN64Z%:QQ!JR$U=5!Q30 F MF51QP[8UX=%&N_I?N?)OM5@GJ
M'X7;\(%/J4-EQ]7?\+7J<$_[H]33*LI6=>3\.S0;@;X5I>FI\NKJ,1EA/%TZ
M^444EBX+&)JTM.0AOWJ^C!)YR_>.NO,"ZKS"R[@0IR[B=/]Z)(?@US0$/"\A
MQE5FI3?]K:D(;TA06?*ZR]4HU09!<!'B>BL@;B3$#)2^HXIKX-. DPV-7 M_
MIVS0T)78JP=@<"HWT\\$>B&YJ 58[A14=6_</%E[">YHZ=#VZ^>7G*^MF\/6
M-I;OK2R+F&U=M^\IT^NV7;>S4.@9SOS6VR0K[!FX2?(G]FW^W!;-VYLR57M-
MVH39:-*I](0=Q>TG[N%]T6EGMXYN8I-+MNBN!1J>Q_ V?A+7=+8:H[M[(O-2
MJ=(P+W2=P^KAL3X0X&R4BN#CQK8H*7.C[J &X9,&Y7%1IE__^!3(5"?1E[A'
MJEN^\.(RB=97$8I:2%D)H%RW;4R1Q!MD"=8')>^%UM=G1FJ]A1'EH*:N^T^C
M/<K'ZZFA)VI9Y'2VOERE*C[+N,4.(J^-V9>_%9%@'95;,5LL*-)(9B/A,\QK
M8DZE?9>.D\5HJM.PTC-7NMTX5W\])Y4(OFDSTB U&\0@57;"+P00<R[0.\2E
MO3W<_/,%]\1O8A;<]V?'MS K?1"AB-@_/I\>,C_V"LS4O\+Y2$HNTZB;..K&
MKR"Z;<M)GO\,]@JOX#OX>K1[_O?3_;-F+#;<%F##>?ZD2+."E\=^ICM-TFH[
M4[76.+> .5V\G&["M>Q6]>"%.C@3E1OJ_2*<E+L _'*Q,2V75W&?KF"X[['<
M#H7[7X9";1H<3E1%*N:H"N". U%$N%\ ZZMV0OQ'^#?7EA961E:W$/*D98].
M6]?->]8T;*OMNKU["G4?L#ABF^NY.-)TE^PM.\DD>Y(]R?YG9&^WK:?)OJQ@
M799H=O<.!OOG[//!<8L=' V6KK'.6YEUGEI2*Y(]R9YD3[+_2=F_\3#CR29_
MW3*_>Q#X]ANWQ$(3^. )G%] I7E<WWG\/.F_U*&8AQR!:09^;F[(,YW9ACS"
MUH,G=CO;9H.1B-B9-XK3M=U_]\Y=+Y(]R;Z1LF\0TY53-___1WR\Z."2*!\K
MRO+_S_'8Y5L*&71U-_439G;MEH'G?(%ARK;53DWIUU>8#492!&Q?W5J NX".
M\;2]^*';0!M['KK9X\/V,/8GG_[T87N4C\-/_Q]02P,$%     @ *8#&5(\D
M1I<, P  IPD  !$   !A8V5T+3(P,C(P-C V+GAS9+U6;6_:,!#^WE]QRZ=6
M6UZ@HFJCTHJ554*BW02MU&^520ZPYMB9[13X][.3F(86$.VD(23,W7-WS[TY
MN;Q>9@Q>4"HJ>-=K!9$'R!.14C[K>H]COS>^&0R\ZZNCRR^^#_W;P3W<XP)Z
MB:8OV*<J84(5$N%X?'<"3]]'0Q@G<\P(]$529,@U^##7.H_#<+%8!.F4<B58
MH4TX%20B"\'W:^<W$HF50Y]HA+@=M=M^=&:^#ZU.?-J..^?!>>>\]36*XBAJ
MF(E\)>ELKN$X.0%K96)SCHRMX)9RPA-*&(Q=T&\PX$D /<9@9*T4C%"A?,$T
MJ'PN51JK*@=-Y SU/<E0Y23!KM?(A*0T03VAHLS"AHW.HC,/B-:23@J-MT)F
M?9R2@NFN5_ _!6%T2C$U!69H*[,!:*A-1[B*D1=9>QUQ.9$L$')F T4A+C5R
M12<,?0M#6=9-^6W;OLK<9+%!=W%:FT>M\.EN6#7)@1GEOS?0C7#1:6C5$Z+0
MP0OESPC)UQ93HB8ENE:4U7#@%.EF%@J38"9>0J/8 %IEJK=E''7"2MF$TCV$
MS8QIT_<U8=,[?5#S:O?OZE%7KW5Q<1&66N_J"* <%9KE0FJH)F8HDK(5>[C9
M?[XCZ%N1WVK[IZW ./. ;YVU'=F%_T;"M?53)-8S\5D2KJ<V>F=7W*U#<%!$
MM6O<[,&WA[TQWPWIQX)NW8@0F59.LI?"]H5ZI4 X%[J,:T5.F.>43T4E,3+;
MH=BU:813* <W)C*1@N'^\0YS*7*4FJ)J;G_I8"YQVO7L2OEN<9X9F01F=QSD
M78#-V;'JT)@@&[[2<[:::FL\M&H%Y:XYS2HW"F7JS^JQ^^]YYA(_FJ<Q4>:R
M+[NU.]U?#=3!25O_#T8/]O X&AQPQ86:+ 47V:HBYQ[2[K?'TQ_<4%H-S"3)
MK*3C 36/DI&!/Q\$=QP=RQ3-,Y^6P]J*[,>\$31>#M9'XPPJ;]!P=QF^=?+&
M?:$P_<FORO/;6M?&-62/84)84K"/V[W2VFE6"UVOZH4-WVQL+6CL=26I;IFK
MOU!+ P04    "  I@,949_^>= P&  #C.   %0   &%C970M,C R,C V,#9?
M;&%B+GAM;,V;\6^C-A3'?[^_XBW[Y4X[0D)WIS6Z]I2E[12MUU9-3CMMFDX$
MG,0:L2-#FN2_GVTP#6!(+JFA4J52>/Z^SP-LX*O73Y\WBP">$ LQ)1>M;KO3
M D0\ZF,RNVA]'5G]T6 X;'V^?//I)\N"JYOA'=RA-?2]"#^A*QQZ 0U7#,';
MT9=W\.WWQUNXQ>2_B1LBN*+>:H%(!!;,HVC9L^WU>MWVIYB$-%A%/&'8]NC"
M!LM*Y <,N6(_7+D1@I[3<1RK\Y'_C+L?>F=.[\-O[?/NKQ]_Z71ZG<[.,+K<
M,CR;1_#6>P=B%,]-" J"+=Q@XA(/NP&,5-+W,"1>&_I! (]B5 B/*$3L"?GM
M6#/@%?0"5<8FQ+W0FZ.%>TL]B7?1VJEG,V%!F[*9[70Z9W8ZJC1"_&6I,$OL
MLKJ.==9M;T*_!?QJD%#F/B")"M\4XM=G,KI[?GYNRZ-I:(AU@5RV:W_[<CN2
M=5K\"D7\K*'6Y1N Y'2X$Q2(2PM2K\=H@"H0Q6$[22SC(QR) :E,NG^[Y+O1
M)D+$1[Y,F*:D7B8H$*>?,C5RSM T)@@Y@DP?(J\]HT^VC[ M;@.Q88D-<7)_
MYG]\'U!^K_<G8<1<+U)*$NJB53QNF\;I\_GABSER$[@S#4[VN'&< 8ZV?3X'
M!]1'NI.S>]@XC%H^'A##U+\FOE@4-%3ZN-KPQERQ@DH>-@YS32)Q;7R?H3!,
M?O%9AKH:LO+8QC"='\!T:L84-_T]&],UV0>Y$UDOX@/ERW7P-UZ6S-N*X'I!
M1Q&?FO?L@=$G+!XO>U#SX37!#OBT96XPY ^DS9]H6TJ9CZL)[WJ!V(R_GOW!
MZ#J:#^ABZ9)R2'UT7:B;,7-)B,5+4[P\EW,60VN"O,$!NELM)HB5PNV$U 3%
MWU I6U(FWS?E/!C0%;_=MI53O'I4;>A3RA82X89O(':+9FYPSQ[1#(<18LB_
M<Q=5-1PTO*9BXJS\SHPJH7-A-<&-W<W0YXL0GN+XPV3/;5P6;QQ7?#@%#W-*
MRB=:(<0XU /CLV/!W]$\)%[4AF&X0FPL/D/8_72JA=P[I&[H'\*M%72$O!7C
M]US7F8S%IY\&KQ!2&]3UQIN[9(9*YK0VS#P<#;#'GW]D]H4OW R[@0ZM&&0<
MC#^8A1TTVBXF5,>4/6X<YR]^:2)$Q)V](LE"%FJP]'%9/!$MG!&^)?PN1*RO
MHZPSP=]#Z8IIWU4S7L'W8)*>FX.\$:'3NI0:\(]2^?>3_9SEY4@S-L*1I*D&
M"!$SG+L&P[$GE$N T  A8@93ZS@<R9N:I+$8<#7I?IHE%Z[$J<!"PPQEJ4-Q
M)'*L!XG2>[4AG&H$]Z3F*AP358S7M(8JGAV.%ZI!SE;*0$C6P)_Q/EZHA%@3
MN*C!%:?*%GFA.J2JN!9*UV0E.>ODM!(2,9!JP.5,DFO]E-/XE23$FI"(&JVB
MX+:<6,(&G@631YE)_F=#YC1NH0.QD$G<2E_FM HRTCNS.$E@?$TZS*XYM<8T
MQWN(LX!,(PI]3@0BD\E:LR[/:34]:QG'+K%]3N/GHI!5-3J/\O;0D?!2!J2.
M4=Q]1M&1^%S6\G9T(1:&6!FD="T%&2C%? UYO^E(<CD6Z!2ZSMO).U"J9IEW
MK:@CN944*"V#"T_1ICH6.A4"I62&.&-B'7MGQ!H0BYCAU+I:1_(F6I 5J^3N
MLZRAYS)/)>:;>W(G$;9'^:1?1E:,D0R?,KK0]>"H=+3,="LZ>G5 :CMW%&31
M;VL&4M?/DY[(O-?6#&)EEX]B+3?<FH7>[?W)LZ866S.(>SN"%&^UV?:ZX)U#
MX9W7 E_L'M*BYXRU5P"N[2G2LA=-M5> 7])II"U YZ<U64))_U&67>>@-0E=
MV96412^WT!HMH+17*4>OM\Z:1"]V,&61<VY9DZ@']35EZ?>;9\T6]"/=3OG*
M#O;.FBQ1WP.5+45CC36)O*<S*LM>Y8\U4T19OY3BUKIAS: >VD6ET ]RQEY%
M*8<7\3KPRSJN%+36_FH65=>'E<<M.%\-(9=V9Z7 >L^K&5QMSY8B+7I=S4!6
M=G(IV'+#2T+ONE7\R^^_RS=J#X[_2>[R?U!+ P04    "  I@,94TN-6=,X$
M  "V*0  %0   &%C970M,C R,C V,#9?<')E+GAM;-U:6V_B.!A][Z_P9E]F
MM!MR8=MM4>F(I66$EEX$C':T+Z.0?("UCAW9H<"_W\^!$"X)M ]D-Y6J$N)C
M^QS[^WPYXO;+(F3D%:2B@C<-IV8;!+@O LHG3>/;P&P-VMVN\>7NXO8GTR3W
MG>X3>8(Y:?DQ?85[JGPFU$P"^31X_$R^_]'OD1[E_XP\!>1>^+,0>$Q,,HWC
MJ&%9\_F\%HPI5X+-8NQ0U7P16L0TU\VW)7CZ/;GW8B -UW9=T[["OZ%SV:B[
MC<OKVO5-_?H7VV[8]E8U$2TEG4QC\LG_3'0M[)MS8&Q).I1[W*<>(X.TTU])
ME_LUTF*,]'4M1?J@0+Y"4%NUR5!!@Z4R%HHVE#^%T.L)/Z'7-+;T+$:2U82<
M6*YMUZU-K4*$_F:F,%._,AW7K#NUA0H,@K/!5=+W&SI)X8L#_+R>H)V;FQLK
M*=U %<T#8K..]?VQ-TATFCA#,8X:&'<7A*R&0PH&?1@3_?FMW]UIQ NH#_&(
MBF0Z]?C;5_:5%7L+P46XM'0=*XV&]+/%@P<>TWC9Y6,APV1@D672V53"N&EX
MV*B9MJ:'Y^<^-O3C/0W%RPB:AJ)AQ,"P,C61Q!GG<8+5\;J&:Z+G58:O=1?[
M_>_RA44,/( @&?Z4,A/^#HCI8!1R=\@T=87<DWA1X-<FXM4*@";4]4,RGLE8
MXI<?;8&9WQJI6'I^G+;$O!&PIG%8;IV;3@M'+] CV&'>)(?.;OG9Z;1Q"ENX
M(K5% 'F#LUU\=C)I<+V I +C*]!+9 ZK?%QI](;8XA%62?'9R:RRKQ4$F&5J
M_8%9!DX.LV+L?T;3?0=-MV2:.NB?Y5#,^2F26\AR*;X(W+S8WS0JR-LCX'*)
M#G#]AV?Y(L4KU9OM":K[\)+(MC%MI<>ZN"$M_H1E(<M]7$GT'D*0$SRL?I5B
M'D_;(HP\7DPR'UT6U<50>EQ1O>FOEN=BGH?0DDAV*(.G63@"64AN"U(2*3RO
M"QD)F9R7DCQHBQF&V_)HBA^O51KUS1FP@P\@>S#QV+/LPX2J&"0$3UYX3,.;
MJI<D9M4K1F9\E/0>K"1R0V_1#7 1HF.ZNJ:=".,B_-GIZFLD>YD*7IQH!Y"S
MDWJ1F!TAGM%\T >UKE(SD$-]#9'/XW$NR9-5RB;]+KJE$AV /Y,8<XX[&NH;
M8 Z] TAII!X6_M3C$RC(Z5S8^<D)1GW<__CD$1=N23V61^T0='9BN#%K<VRP
M#$<BC]-N^=GI_(53$P/7D3WCZX5,Y=#*Q^W0VS8E6G*7JB?]M%%\//!)=OVI
M-<**/(GMF?Z4LLU19RQ%F&<NI+V)O*L^$1)SM6DXMNW8VJ*,\$BD8[)IX&5I
MII",B#3M_0#X/TG:M1,VBIQZ9145>!+99+F5E[;R,S)%=F45'3%%,GDW'TZ>
MNR//^1#RMDV8;!WY(*&Y9]]D^JJ[F!QW?3*%U=W;"JRB+/-^J[BT ILI$WA9
M=8$YYM1&G5OUM67;U<KF[*KBJD[88IG0WRLO]&TF6K:45CT=]YVV;"ZK>UTX
M8=-E$J\K*_'0VLM"LKI;X&EO,%-9W1O$,3,QTU?=V#ST(+/]O;HGSWP3<Z.L
M7MVLRW- LSBL[I:^9Z!F05C="UZ!"9O-UMM.FK?6@;(>OKB[6!?H?_IW?W?_
M E!+ P04    "  I@,94G(3P\ZXG  !69@( #P   &%C970M97@Y.5\Q+FAT
M;>U]:7?C.++E]_<K<+).UI.[)%F+=V?5M%)R5;G'SO2QW=TSG^9 )"2BDB3X
M"%"R^M=/!$!*E"RG[?0BR8[LQ38%8@G<N+%@T:? 1.%O_\4^!8+[\)-],M*$
MXK>3_U,[/*PW/VV[/Z' =E[B4U_Y$U>2]T/!M)F$XM</$4^',JZ%8F".>&;4
M<5^EODAK.N&>C(='C6-;O!;RB<K,T4#>"/]X+'T3'#4;C7KC8_&"I\*0)UH<
M:9'PE!MQG%>=RF&0U_T!VX<.I$7K(ZEE7X;23(Z*]_-"4,HO2KGF=FUK'WZ#
ML?D/+0*_I(MM!L)VJ-FJ-Q*SI+4^][X-4Y7%/HY)I4?IL,\KC:K]S]9QPGT?
M!%,S*CF"YIH-&1^/002U?BKXMR/[_S5\<#P.I!%6D.(H245MG/+D>"12(ST>
MUG@HA_$1U#*MT0FJJ!-&D11=,N+&U&3LB]A^#MT>J-C4M/R/@%FP#W)AY[V"
M!Z&,1:T8:[VQZUX9\$B&DZ-K&0G-OH@QNU01CXNW^\H8%>45V$9=+Q$=V"&L
MHNC3K1Y\MWZHW$W10!H0:VQ@*':B\*W??OZIN=<X_K2=K.&8931D.O5^_0"_
M'.[LMW9:S=;_:]3_2H8?& _-TN=SH&PW&\G-<=ZKPSWX_4-YP,O0O"80+$G#
M@VD0Z<-!V7KY";)]743E/9*[]:RYY;HP=GV*51KQ\/9 RMWLI!**W(7HDYL
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M607BU2UVS3P1AIC73WDB!<8$:1X&5 OUBF.8! \LBRA6"L 5 MLQFDM?BL$
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MR31W8PVF;/**')J$E24R:A4+6W$@X<=@;[BQ7C>\NQA U.ZPMA,6RF]B:D:
M[,%4]@6ZM*#($H, -'7^"+M\%_D&T]VR"00_;E]AS4[D$0_'?*+=OMG-X2HB
MZ563-#AA4V;CJ.XV@V^A#;1B71-?HK.5A=8CLL199>"3",^E.T%CT4VLI5)_
M6UP]FVVKR6L&QL[2(C.JP>M)@2EM;'S7BWFD&N844/:NYM_Q588[X@/I/$:3
MRB3_TW;/;?3YS.9JLR7GZ!&9%]S75-IXV5$E#/L[/)GK]P+/_9ZB(FM/L3\
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M-C V+FAT;5!+ 0(4 Q0    ( "F QE2/)$:7# ,  *<)   1
M  "  84N  !A8V5T+3(P,C(P-C V+GAS9%!+ 0(4 Q0    ( "F QE1G_YYT
M# 8  .,X   5              "  < Q  !A8V5T+3(P,C(P-C V7VQA8BYX
M;6Q02P$"% ,4    "  I@,94TN-6=,X$  "V*0  %0              @ '_
M-P  86-E="TR,#(R,#8P-E]P<F4N>&UL4$L! A0#%     @ *8#&5)R$\/.N
M)P  5F8"  \              ( ! #T  &%C970M97@Y.5\Q+FAT;5!+!08
1    !0 % $$!  #;9      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
